Takeda's Millennium, Infinity Restructure Oncology Drug License
This article was originally published in PharmAsia News
Executive Summary
Takeda's Millennium oncology arm and Infinity Pharmaceuticals have restructured a licensing agreement involving Infinity's IPI-145 drug for treating blood cancer.